EPIDAURUSHot Line 3Interventional Cardiology
Escalated Single Platelet Inhibition and Anticoagulation in Atrial Fibrillation Post-PCI
Escalated single platelet inhibition for one month plus a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention
Presenting authorKonstantinos D. RizasCross-Cutting Cardiology · Ludwig Maximilians University, Munich, GermanyProf. Dr. med. Konstantinos D. Rizas is Chefarzt of Cardiology at Kantonsspital St. Gallen (HOCH Health Ostschweiz), a role he assumed in March 2026. He previously served as medical director of cardiology at LMU Klinikum Campus Innenstadt and as head of the cardiac catheterization laboratory, and remains an apl. Professor at Ludwig-Maximilians-Universität München. He founded and leads a working group for digital clinical research at LMU and holds specialist qualifications in internal medicine and cardiology as well as DGK certification in invasive electrophysiology.
Overview
Await results before adopting escalated platelet inhibition with NOAC post-PCI in AF-ACS; leaves open optimal antithrombotic regimen.
Key result
Escalated single platelet inhibition for one month plus a NOAC in patients with atrial fibrillation and acute coronary syndrome undergoing PCI has pending results.
Discussion
Expert reaction lands here the moment EPIDAURUS reports.
Key Points
- The trial investigates escalated single platelet inhibition combined with a non-vitamin K antagonist oral anticoagulant in acute coronary syndrome.
- Clinical evaluation focuses on patients with atrial fibrillation undergoing percutaneous coronary intervention across a one-month therapeutic regimen.
- Trial evaluation highlights antithrombotic strategies using non-vitamin K antagonist oral anticoagulant regimens, with clinical study results pending.
Main Result
Absolute Event Rate: 0% vs 0%